{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:23:14Z","timestamp":1785460994032,"version":"3.56.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>When people with cystic fibrosis (PwCFs) are treated with cystic fibrosis transmembrane conductance regulator protein modulator (CFTRm), it leads to changes in body composition. An easy, non-invasive, and reproducible method to assess this is by means of electrical bioimpedance measurement, which complements the information provided by the already-known anthropometric parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seventeen adults with cystic fibrosis in treatment with elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) were recruited for a prospective, longitudinal, single-center study over 12\u2009months. Study variables included weight, body mass index (BMI), and body composition by bioelectrical impedance analysis (BIA) [including fat mass (FM) and fat-free mass (FFM)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 12\u2009months, there was an increase in overweight patients (5.9% vs. 23.5%) and a statistically significant increase in BMI at 6 and 12\u2009months. An increase in FM and FFM was observed at 12\u2009months. The increase was greater in FM (95% CI) from a baseline of 1.77% (0.00\u20133.54; <jats:italic>p<\/jats:italic>\u2009=\u20090.050) at 6\u2009months and 2.64% (0.48\u20134.81; <jats:italic>p<\/jats:italic>\u2009=\u20090.020) at 12\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After treatment with ETI, there was an increase in weight, BMI, and FM more than FFM in PwCF. These changes would be confirmed in long-term studies to improve nutritional management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2024.1477674","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:43:43Z","timestamp":1730954623000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Increased fat mass and obesity risk after elexacaftor\u2013tezacaftor\u2013ivacaftor therapy in young adults with cystic fibrosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Ana","family":"Merino S\u00e1nchez-Ca\u00f1ete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n Marina","family":"L\u00f3pez C\u00e1rdenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saioa","family":"Vicente Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Guti\u00e9rrez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Su\u00e1rez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"\u00c1lvarez Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonz\u00e1lez Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"111124","DOI":"10.1016\/j.nut.2020.111124","article-title":"Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: a double-blind, placebo-controlled, randomized, crossover study with open-label extension","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.5546\/aap.2019.eng.e131","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: present and future in cystic fibrosis treatment. A review","volume":"117","author":"De la Hoz","year":"2019","journal-title":"Arch Argent Pediatr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10620-015-3834-2","article-title":"Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with Ivacaftor","volume":"61","author":"Borowitz","year":"2016","journal-title":"Dig Dis Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"100272","DOI":"10.1016\/j.jcte.2021.100272","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/ncp.10247","article-title":"Tools and methods used for the assessment of body composition in patients with cystic fibrosis: a systematic review","volume":"34","author":"Calella","year":"2019","journal-title":"Nutr Clin Pract"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.arcped.2011.01.008","article-title":"Composition corporelle des patients mucoviscidosiques\u2013comparaison de 3 techniques de mesure: anthropom\u00e9trie, absorptiom\u00e9trie biphotonique et imp\u00e9dancem\u00e9trie","volume":"18","author":"Beaumesnil","year":"2011","journal-title":"Arch P\u00e9diatr"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4103\/ijmr.IJMR_1777_18","article-title":"Body composition techniques","volume":"148","author":"Kuriyan","year":"2018","journal-title":"Indian J Med Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metada-ta-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1002\/ppul.25627","article-title":"Review of CFTR modulators 2020","volume":"56","author":"Goetz","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"ref13","first-page":"26","volume-title":"German cystic fibrosis registry. Annual report 2022","author":"N\u00e4hrlich","year":"2023"},{"key":"ref14","volume-title":"A healthy lifestyle-WHO recommendations","year":""},{"key":"ref15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: exploring the effect on weight and body composition after the initiation of elexa-caftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibros"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0200465","DOI":"10.1371\/journal.pone.0200465","article-title":"Comparison of body composition assessment by DXA and BIA according to the body mass index: a retrospective study on 3655 measures","volume":"13","author":"Achamrah","year":"2018","journal-title":"PLoS One"},{"key":"ref17","volume-title":"Nutritional basics","year":""},{"key":"ref18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.clnu.2012.04.012","article-title":"Use of body mass index percentile to identify fat-free mass depletion in children with cystic fibrosis","volume":"31","author":"Engelen","year":"2012","journal-title":"Clin Nutr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jbmt.2017.04.010","article-title":"Body composition estimation in children and adolescents by bioelectrical impedance analysis: a systematic review","volume":"22","author":"Chula De Castro","year":"2018","journal-title":"J Bodyw Mov Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/ajcn\/80.5.1201","article-title":"Nutritional status is an important predictor of diaphragm strength in young patients with cystic fibrosis","volume":"80","author":"Hart","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastro-intestinal outcomes in cystic fibrosis: report of promise GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expert Opin Drug Discov"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1477674\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:43:46Z","timestamp":1730954626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1477674\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":24,"alternative-id":["10.3389\/fnut.2024.1477674"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2024.1477674","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"article-number":"1477674"}}